Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology
Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin conditions, has announced that it has initiated legal proceedings against SkinCure Oncology, LLC. The lawsuit, filed in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, centers on allegations of breach of contract tied to unpaid balances for medical equipment supplied by Sensus Healthcare.
According to the complaint, Sensus Healthcare alleges that SkinCure Oncology has failed to remit payment for products that were delivered, accepted, and subsequently deployed into clinical use. The company claims that the outstanding balance amounts to several million dollars and relates to equipment delivered under the terms of a Master Product Purchase Agreement between the two parties.
The dispute specifically involves multiple units of Sensus Healthcare’s SRT-100 Vision systems, which are used in the treatment of non-melanoma skin cancers and other dermatological conditions through superficial radiation therapy. These systems are designed to provide targeted radiation treatment while minimizing damage to surrounding healthy tissue, making them an important tool in dermatologic oncology practices.
Sensus Healthcare contends that the equipment in question was delivered to SkinCure Oncology and formally accepted, after which it was integrated into clinical operations and used to treat patients beginning in or around August 2025. Despite this, the company alleges that SkinCure has not fulfilled its payment obligations as outlined in the contractual agreement.
The lawsuit asserts that the unpaid amounts are contractually due and payable, and that SkinCure has failed to meet agreed-upon payment deadlines. In addition to seeking recovery of the outstanding balance, Sensus Healthcare is also pursuing additional damages, the amount of which has not been specified in the filing. The company is further seeking pre-judgment and post-judgment interest, along with reimbursement of legal fees and associated costs.
Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, emphasized the company’s position in a public statement, indicating that Sensus intends to pursue all available legal avenues to enforce its contractual rights. He stated that the equipment at the center of the dispute—ten SRT-100 Vision units—has been fully delivered, accepted, and is actively in use by SkinCure Oncology.
Sardano further noted that SkinCure had previously acknowledged the outstanding debt and had committed to specific payment timelines, which have since passed without resolution. He stressed that Sensus Healthcare expects its customers and partners to adhere to the terms of their agreements, particularly when equipment has been successfully deployed and is contributing to clinical operations.
The legal action highlights the importance of contractual compliance in the medical device industry, where equipment transactions often involve significant capital investment and long-term payment structures. Agreements such as Master Product Purchase Agreements typically outline detailed terms governing delivery, acceptance, payment schedules, and remedies in the event of non-payment. Disputes of this nature can arise when one party alleges that the agreed financial obligations have not been met, despite fulfillment of delivery and performance conditions by the supplier.
While the litigation introduces a degree of uncertainty, Sensus Healthcare has indicated that it does not expect the matter to materially impact its ongoing operations. The company stated that it remains focused on supporting its growing global customer base and executing its commercial strategy, which includes expanding adoption of its radiation therapy technologies across dermatology and oncology practices.
Sensus Healthcare has built its business around providing cost-effective, office-based treatment solutions that enable clinicians to deliver care in outpatient settings. Its product portfolio, including the SRT-100 Vision system, is designed to offer alternatives to more invasive surgical procedures, particularly for patients who may not be ideal candidates for surgery. The company continues to position its technology as a clinically effective and economically viable option within the broader dermatology and oncology landscape.
The dispute with SkinCure Oncology underscores the financial and operational complexities that can accompany the deployment of advanced medical technologies. For providers, acquiring such equipment often involves balancing upfront costs with anticipated clinical and financial benefits. For manufacturers, ensuring timely payment is critical to sustaining operations, funding innovation, and supporting customer service and maintenance.
From a broader perspective, the case also reflects the importance of clear communication and adherence to contractual terms in maintaining strong business relationships within the healthcare ecosystem. As companies collaborate to deliver medical technologies and services, mutual accountability and transparency are essential to ensuring successful partnerships.
Sensus Healthcare has indicated that it is actively pursuing the matter through the legal system and will seek appropriate remedies as the case progresses. At the same time, the company reiterated its commitment to its customers, emphasizing that it will continue to provide support, service, and innovation across its product lines without disruption.
As the case moves forward in the Florida court system, further developments may provide additional clarity regarding the nature of the dispute and its potential resolution. In the interim, Sensus Healthcare remains focused on advancing its mission of delivering effective, non-invasive treatment solutions while upholding its contractual and business standards.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings.
Source Link:https://www.businesswire.com/
